Pro Medicus (OTCMKTS:PMCUF) Shares Gap Up – Should You Buy?

Pro Medicus Limited (OTCMKTS:PMCUF) shares gapped up before the market opened on Monday. The stock had previously closed at $105.09, but opened at $116.33. Pro Medicus shares last traded at $116.33, with a volume of 1 shares changing hands.

Wall Street Analyst Weigh In

Separately, Jefferies Financial Group cut Pro Medicus from a “buy” rating to a “hold” rating in a research report on Wednesday, July 8th. One equities research analyst has rated the stock with a Hold rating. Based on data from MarketBeat, Pro Medicus presently has an average rating of “Hold” and an average target price of $155.00.

Pro Medicus Stock Up 1.1%

The firm has a fifty day simple moving average of $120.59 and a two-hundred day simple moving average of $113.34.

About Pro Medicus

Pro Medicus Limited is an Australian medical technology company that develops software for medical imaging and healthcare organizations. Its solutions are designed to help hospitals, radiology practices and other providers store, manage, view and distribute medical images and related clinical information.

The company’s principal platform is Visage 7, an enterprise imaging system developed and commercialized through its wholly owned subsidiary, Visage Imaging. The platform supports the review of diagnostic studies such as computed tomography, magnetic resonance imaging and other medical images, with an emphasis on enterprise-wide access, workflow efficiency and advanced visualization.

Founded in 1983 and headquartered in Melbourne, Australia, Pro Medicus serves healthcare customers in Australia, North America and Europe.